ArticleBMC cancer2012
Sunitinib treatment does not improve blood supply but induces hypoxia in human melanoma xenografts.
Article in BMC cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 33 citations in OpenAlex.
- A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma.British journal of cancer · 2014Trial
- RTK Inhibitors in Melanoma: From Bench to Bedside.Cancers · 2021Review
- Multiparametric MRI for assessment of early response to neoadjuvant sunitinib in renal cell carcinoma.PloS one · 2021Article
- Article
- Computational models of melanoma.Theoretical biology & medical modelling · 2020Review
- Bevacizumab treatment of meningeal melanoma metastases.Journal of translational medicine · 2020Article
- Vascularization, Oxygenation, and the Effect of Sunitinib Treatment in Pancreatic Ductal Adenocarcinoma Xenografts.Frontiers in oncology · 2019Article
- The Effect of Sunitinib Treatment in Human Melanoma Xenografts: Associations with Angiogenic Profiles.Translational oncology · 2017Article
- Traumatic brain injury results in acute rarefication of the vascular network.Scientific reports · 2017Article
- Autophagy Inhibition Enhances Sunitinib Efficacy in Clear Cell Ovarian Carcinoma.Molecular cancer research : MCR · 2017Article
- Properdistatin inhibits angiogenesis and improves vascular function in human melanoma xenografts with low thrombospondin-1 expression.Oncotarget · 2016Article
- Stroma-derived but not tumor ADAMTS1 is a main driver of tumor growth and metastasis.Oncotarget · 2016Article
- Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging.BMC cancer · 2015Article
- Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction.Cancer medicine · 2015Article
- Article
- Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models.American journal of cancer research · 2015Article
- Detecting functional changes with [(18)F]FAZA in a renal cell carcinoma mouse model following sunitinib therapy.EJNMMI research · 2014Article
- The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities.Antioxidants & redox signaling · 2014Review
- In vivo spectral and fluorescence microscopy comparison of microvascular function after treatment with OXi4503, Sunitinib and their combination in Caki-2 tumors.Biomedical optics express · 2014Article
- Magnetic resonance imaging identifies early effects of sunitinib treatment in human melanoma xenografts.Journal of experimental & clinical cancer research : CR · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntiangiogenic agents that disrupt the vascular endothelial growth factor pathway have been demonstrated to normalize tumor vasculature and improve tumor oxygenation in some studies and to induce hypoxia in others. The aim of this preclinical study was to investigate the effect of sunitinib treatment on the morphology and function of tumor vasculature and on tumor oxygenation.
methodsA-07-GFP and R-18-GFP human melanoma xenografts grown in dorsal window chambers were used as preclinical tumor models. Morphologic parameters of tumor vascular networks were assessed from high-resolution transillumination images, and tumor blood supply time was assessed from first-pass imaging movies recorded after a bolus of 155 kDa tetramethylrhodamine isothiocyanate-labeled dextran had been administered intravenously. Tumor hypoxia was assessed from immunohistochemical preparations of the imaged tissue by use of pimonidazole as a hypoxia marker.
resultsSunitinib treatment reduced vessel densities, increased vessel segment lengths, did not affect blood supply times, and increased hypoxic area fractions.
conclusionSunitinib treatment did not improve vascular function but induced hypoxia in A-07-GFP and R-18-GFP tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.